{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:35:29Z","timestamp":1793086529615,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The evidence regarding an association between the nitrofuran and sulfonamide classes of antibiotics and birth defects is mixed. As with all patients, antibiotics should be prescribed for pregnant women only for appropriate indications and for the shortest effective duration. During the second and third trimesters, sulfonamides and nitrofurantoins may continue to be used as first-line agents for the treatment and prevention of urinary tract infections and other infections caused by susceptible organisms. Prescribing sulfonamides or nitrofurantoin in the first trimester is still considered appropriate when no other suitable alternative antibiotics are available. Pregnant women should not be denied appropriate treatment for infections because untreated infections can commonly lead to serious maternal and fetal complications.<\/jats:p>","DOI":"10.1097\/aog.0000000000002300","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T18:30:31Z","timestamp":1503513031000},"page":"e150-e152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Committee Opinion No. 717: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects"],"prefix":"10.1097","volume":"130","member":"276","reference":[{"key":"R1-20261027","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archpediatrics.2009.188","article-title":"Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study","volume":"163","author":"Crider","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R2-20261027","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200011303432204","article-title":"Folic acid antagonists during pregnancy and the risk of birth defects","volume":"343","author":"Hernandez-Diaz","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-20261027","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0890-6238(01)00178-2","article-title":"The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study","volume":"15","author":"Czeizel","year":"2001","journal-title":"Reprod Toxicol"},{"key":"R4-20261027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1741-4520.2004.00012.x","article-title":"Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy","volume":"44","author":"Czeizel","year":"2004","journal-title":"Congenit Anom (Kyoto)"},{"key":"R5-20261027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2036.2001.00962.x","article-title":"Population-based case control study of the safety of sulfasalazine use during pregnancy","volume":"15","author":"Norgard","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20261027","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0301-2115(00)00545-5","article-title":"Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case\u2013control teratologic study","volume":"97","author":"Czeizel","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R7-20261027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0890-6238(90)90042-T","article-title":"A case-control analysis of the teratogenic effects of co-trimoxazole","volume":"4","author":"Czeizel","year":"1990","journal-title":"Reprod Toxicol"},{"key":"R8-20261027","first-page":"24","article-title":"Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings","volume":"8","author":"Forna","year":"2006","journal-title":"AIDS Rev"},{"key":"R9-20261027","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/AOG.0b013e31827c5f88","article-title":"Neonatal outcomes after gestational exposure to nitrofurantoin","volume":"121","author":"Nordeng","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R10-20261027","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1469-0691.2002.00368.x","article-title":"Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero","volume":"8","author":"Dencker","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"R11-20261027","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1067\/mob.2001.113907","article-title":"A population-based case-control teratologic study of ampicillin treatment during pregnancy","volume":"185","author":"Czeizel","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20261027","first-page":"379","article-title":"A follow-up study of birth outcome in users of pivampicillin during pregnancy","volume":"79","author":"Larsen","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R13-20261027","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0002-9378(02)70079-3","article-title":"Use of cephalosporins during pregnancy and in the presence of congenital abnormalities [letter]","volume":"187","author":"Berkovitch","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R14-20261027","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0020-7292(01)00345-9","article-title":"A population-based case-control teratologic study of nalidixic acid","volume":"73","author":"Czeizel","year":"2001","journal-title":"Int J Gynaecol Obstet"},{"key":"R15-20261027","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/003655400458992","article-title":"A teratological study of lincosamides","volume":"32","author":"Czeizel","year":"2000","journal-title":"Scand J Infect Dis"},{"key":"R16-20261027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/00365549950163635","article-title":"Teratogenic evaluation of oxacillin","volume":"31","author":"Czeizel","year":"1999","journal-title":"Scand J Infect Dis"},{"key":"R17-20261027","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0890-6238(99)00046-5","article-title":"A population-based case-control teratologic study of oral erythromycin treatment during pregnancy","volume":"13","author":"Czeizel","year":"1999","journal-title":"Reprod Toxicol"},{"key":"R18-20261027","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/jac\/44.6.854","article-title":"Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women","volume":"44","author":"Sorensen","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"R19-20261027","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0301-2115(95)02524-3","article-title":"Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)","volume":"69","author":"Schaefer","year":"1996","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R20-20261027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0924-8579(01)00390-9","article-title":"Birth outcome following maternal use of fluoroquinolones","volume":"18","author":"Larsen","year":"2001","journal-title":"Int J Antimicrob Agents"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201709000-00048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:00:33Z","timestamp":1793084433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201709000-00048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002300","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"2017-08-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}